Seven-year follow-up study of bromocriptine therapy for parkinson’s disease

European Neurology

Volumn 34, Issue , 1994, Pages 29-35

  Yanagisawa, N ^a   Kanazawa, I ^b   Goto, I ^c   Kowa, H ^d   Kuno, S ^e   Mizuno, Y ^f   Tashiro, K ^g   Ogawa, N ^h  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d KITASATO UNIVERSITY HOSPITAL   (Japan)

^e UTANO NATIONAL HOSPITAL   (Japan)

^f JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g OKAYAMA UNIVERSITY   (Japan)

^h HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Bromocriptine; Dopamine receptor agonists; Long term treatment; Neuroprotective therapy

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; BROMOCRIPTINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

ADULT; AGED; CONFERENCE PAPER; DISEASE COURSE; DYSKINESIA; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PARKINSON DISEASE; PRIORITY JOURNAL;

ADULT; AGED; BROMOCRIPTINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMAN; LEVODOPA; LONG-TERM CARE; MALE; MIDDLE AGE; NEUROLOGIC EXAMINATION; NEURONS; PARKINSON DISEASE; SUBSTANTIA NIGRA;

EID: 0028133286     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000119539     Document Type: Article

References (7)

1. Lieberman A: Dopamine agonists used as monotherapy in de novo PD patients: Comparisons with selegiline. Neurology 1992; 42(suppl 4):37-40.
2. Nakanishi T, lwata M, Goto I, Kanazawa I, Kowa H, Mannen T, Mizuno Y, Nishitani H, Ogawa N, Takahashi A, Tashiro K, Tohgi H, Yanagisawa N: Nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients (final report). Eur Neurol 1992;32(suppl I):9-22.
3. Nakanishi T, Kanazawa I, lwata M, Goto I, Kowa H, Mannen T, Mizuno Y, Nishitani H, Ogawa N, Takahashi A, Tashiro K, Tohgi H, Yanagisawa N: Nationwide collaborative study on the long-term effects of bromocriptine in the treatment of parkinsonian patients: Analysis on the maintenance and the change of the original mode of treatment. Eur Neurol 1992; 32(suppl 1):23-29.
4. Nakanishi T, Mizuno Y, Goto I, lwata M, Kanazawa I, Kowa H, Mannen T, Nishitani H, Ogawa N, Takahashi A, Tashiro K, Tohgi H, Yanagisawa N: A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson’s disease (the fourth interim report). Eur Neurol 1991;31(suppl 1): 3-16.
5. Clow A, Hussain T, Glover V, Sandler M, Walker M, Dexter D: Pergolide can induce soluble Superoxide dismutase in rat striata. J Neural Transm 1992;90:27-31.
6. Ogawa N: Perspectives of the treatment of Parkinson’s disease (in Japanese). Shinkei Chiryogaku 1993;10:193-201.
7. Felten DL, Felten SY, Fuller RW, Romano TD. Barrysmalstig E, Wong DT, Clements JA: Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats. Neurobiol Aging 1992;13:339-351.